TL;DR
GLP-1 compounding pharmacies face a coverage crisis: several specialty pharmacy carriers added non-FDA-approved drug exclusions to renewal endorsement schedules in 2025 and 2026, sometimes mid-policy. The compliant 503A and 503B programs that exist are tightly scoped, with manuscript language, named-peril structure, and narrow geographic reach. We place the available capacity and document the exposures the operator must address through process, not insurance.
GLP-1 Compounding · Coverage Crisis
Several specialty pharmacy carriers added GLP-1 exclusions to renewal endorsement schedules in 2025-2026 - often without prominent disclosure. If you compound semaglutide or tirzepatide and your endorsement schedule contains a non-FDA-approved drug exclusion, your products liability for that revenue line is uninsured.
We help GLP-1 compounders find markets that will write the exposure with disciplined underwriting, and help you decide whether to invest in compliance posture or wind the line down.
Problem 01 · The exclusion
Many specialty pharmacy carriers added exclusions for compounded versions of FDA-approved branded drugs starting in 2025-2026. The exclusion language varies - some target only semaglutide and tirzepatide explicitly; others use broader language excluding any non-FDA-approved drug. The exclusion is often added at renewal without prominent disclosure.
Read the endorsement schedule before signing. Search for terms like "compounded," "drug shortage," "FDA-approved," and "biosimilar" in the exclusions section. If your carrier added an exclusion at renewal and you missed it, your products liability for the GLP-1 revenue line may be uninsured.
Problem 02 · The market
Wholesale-placed specialty markets and London-market layers will write GLP-1 compounding exposure with disciplined underwriting. Expect requirements for volume caps by product, BMI distribution of patients, prescriber relationships and supervision documentation, telehealth platform controls, and prescription audit trails.
Quote validity windows are short - typically 7 to 14 days. The market posture changes faster than most renewals can move; work with a broker who is in the market weekly, not quarterly.
Problem 03 · The strategic question
The regulatory and litigation environment is volatile. The coverage problem is the immediate pain; the strategic question is whether to invest in compliance and underwriting discipline to make GLP-1 compounding insurable as a sustainable business line, or to wind it down and pivot revenue to alternative therapeutic categories.
We can help with the insurance question - we cannot make the strategic call for you. What we can do is map the underwriting requirements onto your operations and tell you what investing in insurability would cost relative to revenue concentration risk.
Problem 01 · Carrier exclusion verification
Several specialty pharmacy and 503B carriers added non-FDA-approved drug exclusions, GLP-1 exclusions, semaglutide/tirzepatide-specific exclusions, and weight-loss drug exclusions to renewal endorsement schedules across 2025 and 2026. Some were issued mid-policy. Some were renewal additions without prominent disclosure.
If your endorsement schedule contains any of these exclusions, your products liability for the GLP-1 line is operating uninsured. Verification is a mechanical search through every endorsement document; we run this check quarterly for clients.
Problem 02 · FDA shortage list status
Compounded GLP-1 production scope depends on whether semaglutide and tirzepatide remain on the FDA Drug Shortage List. The status changes over time and carries specific procedural implications for 503A (patient-specific prescription requirement) and 503B (non-patient-specific production) operators.
Insurance underwriting now actively asks for documentation of current shortage list status and the operator's regulatory framework justification. Programs require ongoing tracking and documentation as the shortage status evolves.
Problem 03 · Markets still writing the segment
The specialty pharmacy carrier panel that was actively writing GLP-1 compounders in 2024 narrowed substantially through 2025 and 2026. The markets remaining are pricing materially above pre-2025 baseline and require more documentation than the previous standard submission.
Underwriters now expect FDA shortage status documentation, patient-specific prescription tracking (for 503A scope), 503B regulatory standing (for non-patient-specific production), state board authorization, and a documented regulatory rationale for continued production.
Problem 04 · Wind-down vs continue decision
For some operators, the right answer is to wind down GLP-1 production rather than continue. The insurance market is now signaling which segments will remain insurable at acceptable cost vs which will face escalating carrier withdrawal.
The decision combines regulatory pathway analysis, customer-base economics, and insurance availability. We work with operators and counsel on the integrated assessment rather than treating it as a pure insurance procurement question.
Carrier access
The number of carriers willing to underwrite GLP-1 compounding narrowed substantially in 2025-2026. Generalist pharmacy markets exited the segment; the remaining capacity sits with specialty life-sciences and surplus-lines markets that understand the regulatory framework.
Our placements run through the carriers and Lloyd's-backed paper still writing the segment, with appropriate documentation of regulatory standing. We coordinate with state boards and the FDA Drug Shortage List status to support underwriting submissions.
Programs anchored in Texas with broader placement across the major US life-sciences clusters - including the New Jersey pharma corridor and the North Carolina (RTP) cluster.
Pricing
Premium ranges for 503A and 503B GLP-1 compounders post-2026 enforcement, the factors that drive cost, and sample programs.
Frequently asked
FDA issued warning letters to several large-scale GLP-1 compounding operations and reaffirmed that semaglutide and tirzepatide are no longer on the drug shortage list. The safe harbor for compounding identical or essentially-similar copies under 503A and 503B narrowed significantly.
Depends on the carrier and endorsement. Many specialty pharmacy carriers added exclusions for non-FDA-approved drug claims starting in 2025-2026, often without prominent disclosure. Read your renewal endorsement schedule carefully.
Yes, but the market is narrowing. Wholesale-placed specialty markets and London facilities will write it with disciplined underwriting - volume caps, BMI screens, telehealth controls, prescription audit trails. Pricing is moving and quote validity windows are short.
Volume by product, BMI distribution of patients, prescriber relationships and supervision documentation, telehealth-platform integration controls, lot tracking, and cGMP or USP 797 documentation depending on 503A vs. 503B status.
The regulatory and litigation environment is volatile. The coverage problem is the immediate pain; the strategic question is whether to invest in compliance and underwriting discipline to make GLP-1 compounding insurable, or to wind it down. We can help with the insurance question; the strategic question is yours.
Next steps
Five questions. Verify whether your renewal endorsement silently added a non-FDA-approved drug exclusion.
OpenPaste 3 customer contract indemnity clauses. Get a verdict on the risk transfer architecture.
OpenFor 503B outsourcing facilities with GLP-1 exposure, the structures that survive the new carrier underwriting environment.
OpenFive compounding pharmacy structures, including the GLP-1 carrier-exclusion review every renewal now requires.
OpenAuthoritative references
FDA position on compounded semaglutide and the resolution of the shortage list.
Active shortage status determines whether compounded GLP-1 production is permitted.
BUD assignment for sterile GLP-1 injectable compounding follows USP 797.
Defines patient-specific prescription requirement for traditional pharmacy GLP-1 compounding.
503B path for non-patient-specific GLP-1 production - different regulatory standard than 503A.
Why operators choose this practice
Every placement passes through specialty life-sciences underwriters - not a general manufacturer or healthcare desk.
Programs placed nationally with deep practice content for the 16 states anchoring the major US life-sciences clusters.
Coverage review requests come back the same business day. MSA reads are typically half an hour or less.
Free MSA Decoder, 49-clause glossary, 60+ Q&A library. Designed for CFOs, GCs, and Quality leaders.
Related deep-dives
Free coverage review
No marketing sequences, no list rental. Half-hour MSA reads are the standard.